Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.34 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.34 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.34 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23594478 | 0.85 | KMT2A (0.40) | KDM4ETDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL21016002 | 0.85 | HSD11B1 (0.54) | HSD11B1KDM4ETDP1ALDH1A1KMT2A | |
| SCHEMBL23594013 | 0.84 | NPC1 (0.36) | HSD11B1KDM4ETDP1ALDH1A1KMT2A | |
| SCHEMBL21015519 | 0.83 | HSD11B1 (0.53) | HSD11B1TDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL23484910 | 0.82 | GAA (0.44) | RAB9ANPC1TPSAB1TPSD1TPSG1 | |
| SCHEMBL21015277 | 0.82 | HSD11B1 (0.51) | HSD11B1TDP1ALDH1A1KMT2AMEN1 | |
| SCHEMBL24926114 | 0.82 | HRH3 (0.41) | KDM4EALDH1A1L3MBTL1NPC1TPSAB1 | |
| SCHEMBL26827456 | 0.82 | NPC1 (0.34) | HSD11B1KDM4ETDP1ALDH1A1KMT2A | |
| SCHEMBL16938386 | 0.81 | HSD11B1 (0.61) | HSD11B1KDM4ETDP1ALDH1A1KMT2A | |
| SCHEMBL23594007 | 0.80 | TPSAB1 (0.33) | HSD11B1KDM4ETDP1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | HSD11B1 3457/4885KDM4E 1076/4885TDP1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.